HomeCompareFIOFX vs MRK

FIOFX vs MRK: Dividend Comparison 2026

FIOFX yields 2.12% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $7.9K in total portfolio value
10 years
FIOFX
FIOFX
● Live price
2.12%
Share price
$29.59
Annual div
$0.63
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$242.56
Full FIOFX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — FIOFX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIOFXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIOFX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FIOFX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIOFX
Annual income on $10K today (after 15% tax)
$179.82/yr
After 10yr DRIP, annual income (after tax)
$206.18/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $601.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIOFX + MRK for your $10,000?

FIOFX: 50%MRK: 50%
100% MRK50/50100% FIOFX
Portfolio after 10yr
$26.8K
Annual income
$596.43/yr
Blended yield
2.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FIOFX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIOFX buys
0
MRK buys
0
No recent congressional trades found for FIOFX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIOFXMRK
Forward yield2.12%3.25%
Annual dividend / share$0.63$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$22.8K$30.7K
Annual income after 10y$242.56$950.29
Total dividends collected$2.3K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FIOFX vs MRK ($10,000, DRIP)

YearFIOFX PortfolioFIOFX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,912$211.56$11,192$351.54$280.00MRK
2$11,891$215.74$12,524$392.70$633.00MRK
3$12,943$219.73$14,015$438.65$1.1KMRK
4$14,073$223.52$15,682$489.96$1.6KMRK
5$15,285$227.13$17,547$547.23$2.3KMRK
6$16,585$230.56$19,632$611.16$3.0KMRK
7$17,980$233.81$21,963$682.53$4.0KMRK
8$19,476$236.89$24,571$762.18$5.1KMRK
9$21,079$239.80$27,486$851.08$6.4KMRK
10$22,797$242.56$30,745$950.29$7.9KMRK

FIOFX vs MRK: Complete Analysis 2026

FIOFXStock

The investment seeks high total return until its target retirement date; thereafter the fund's objective will be to seek high current income and, as a secondary objective, capital appreciation. The fund invests in a combination of Fidelity® U.S. equity funds, international equity funds, bond funds, and short-term funds (underlying Fidelity ® funds), each of which (excluding any money market fund) seeks to provide investment results that correspond to the total return of a specific index.

Full FIOFX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this FIOFX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIOFX vs SCHDFIOFX vs JEPIFIOFX vs OFIOFX vs KOFIOFX vs MAINFIOFX vs JNJFIOFX vs ABBVFIOFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.